The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Hospital Acquired Pneumonia Drugs-Global Market Insights and Sales Trends 2024

Hospital Acquired Pneumonia Drugs-Global Market Insights and Sales Trends 2024

Publishing Date : Dec, 2023

License Type :
 

Report Code : 1860344

No of Pages : 102

Ask Your Query
Synopsis
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.
The global Hospital Acquired Pneumonia Drugs market size is expected to reach US$ 3218.1 million by 2029, growing at a CAGR of 1.5% from 2023 to 2029. The market is mainly driven by the significant applications of Hospital Acquired Pneumonia Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies, Drug Store and E-Commerce, are propelling Hospital Acquired Pneumonia Drugs market. Phase II, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Early Phase (Phase I & II) segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hospital Acquired Pneumonia Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hospital Acquired Pneumonia Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hospital Acquired Pneumonia Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hospital Acquired Pneumonia Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hospital Acquired Pneumonia Drugs covered in this report include Basilea Pharmaceutica, Meiji Holdings, Cubist Pharmaceutical, Aridis Pharmaceutical, Valneva, Bayer, GlaxoSmithKline, Merck and Achaogen, etc.
The global Hospital Acquired Pneumonia Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Basilea Pharmaceutica
Meiji Holdings
Cubist Pharmaceutical
Aridis Pharmaceutical
Valneva
Bayer
GlaxoSmithKline
Merck
Achaogen
AstraZeneca
Global Hospital Acquired Pneumonia Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hospital Acquired Pneumonia Drugs market, Segment by Type:
Phase II
Early Phase (Phase I & II)
Global Hospital Acquired Pneumonia Drugs market, by Application
Hospital Pharmacies
Retail Pharmacies
Drug Store
E-Commerce
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Hospital Acquired Pneumonia Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Hospital Acquired Pneumonia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Hospital Acquired Pneumonia Drugs Market Overview
1.1 Hospital Acquired Pneumonia Drugs Product Overview
1.2 Hospital Acquired Pneumonia Drugs Market Segment by Type
1.2.1 Phase II
1.2.2 Early Phase (Phase I & II)
1.3 Global Hospital Acquired Pneumonia Drugs Market Size by Type
1.3.1 Global Hospital Acquired Pneumonia Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Hospital Acquired Pneumonia Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Hospital Acquired Pneumonia Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Hospital Acquired Pneumonia Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Hospital Acquired Pneumonia Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Hospital Acquired Pneumonia Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Hospital Acquired Pneumonia Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales Breakdown by Type (2018-2023)
2 Global Hospital Acquired Pneumonia Drugs Market Competition by Company
2.1 Global Top Players by Hospital Acquired Pneumonia Drugs Sales (2018-2023)
2.2 Global Top Players by Hospital Acquired Pneumonia Drugs Revenue (2018-2023)
2.3 Global Top Players by Hospital Acquired Pneumonia Drugs Price (2018-2023)
2.4 Global Top Manufacturers Hospital Acquired Pneumonia Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Hospital Acquired Pneumonia Drugs Market Competitive Situation and Trends
2.5.1 Hospital Acquired Pneumonia Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Hospital Acquired Pneumonia Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hospital Acquired Pneumonia Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Hospital Acquired Pneumonia Drugs Market
2.8 Key Manufacturers Hospital Acquired Pneumonia Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Hospital Acquired Pneumonia Drugs Status and Outlook by Region
3.1 Global Hospital Acquired Pneumonia Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Hospital Acquired Pneumonia Drugs Historic Market Size by Region
3.2.1 Global Hospital Acquired Pneumonia Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Hospital Acquired Pneumonia Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Hospital Acquired Pneumonia Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Hospital Acquired Pneumonia Drugs Forecasted Market Size by Region
3.3.1 Global Hospital Acquired Pneumonia Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Hospital Acquired Pneumonia Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Hospital Acquired Pneumonia Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Hospital Acquired Pneumonia Drugs by Application
4.1 Hospital Acquired Pneumonia Drugs Market Segment by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Drug Store
4.1.4 E-Commerce
4.2 Global Hospital Acquired Pneumonia Drugs Market Size by Application
4.2.1 Global Hospital Acquired Pneumonia Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Hospital Acquired Pneumonia Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Hospital Acquired Pneumonia Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Hospital Acquired Pneumonia Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Hospital Acquired Pneumonia Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Hospital Acquired Pneumonia Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Hospital Acquired Pneumonia Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales Breakdown by Application (2018-2023)
5 North America Hospital Acquired Pneumonia Drugs by Country
5.1 North America Hospital Acquired Pneumonia Drugs Historic Market Size by Country
5.1.1 North America Hospital Acquired Pneumonia Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Hospital Acquired Pneumonia Drugs Sales in Value by Country (2018-2023)
5.2 North America Hospital Acquired Pneumonia Drugs Forecasted Market Size by Country
5.2.1 North America Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Hospital Acquired Pneumonia Drugs Sales in Value by Country (2024-2029)
6 Europe Hospital Acquired Pneumonia Drugs by Country
6.1 Europe Hospital Acquired Pneumonia Drugs Historic Market Size by Country
6.1.1 Europe Hospital Acquired Pneumonia Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Hospital Acquired Pneumonia Drugs Sales in Value by Country (2018-2023)
6.2 Europe Hospital Acquired Pneumonia Drugs Forecasted Market Size by Country
6.2.1 Europe Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Hospital Acquired Pneumonia Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Hospital Acquired Pneumonia Drugs by Region
7.1 Asia-Pacific Hospital Acquired Pneumonia Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Hospital Acquired Pneumonia Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Hospital Acquired Pneumonia Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Hospital Acquired Pneumonia Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Hospital Acquired Pneumonia Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Hospital Acquired Pneumonia Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Hospital Acquired Pneumonia Drugs Sales in Value by Region (2024-2029)
8 Latin America Hospital Acquired Pneumonia Drugs by Country
8.1 Latin America Hospital Acquired Pneumonia Drugs Historic Market Size by Country
8.1.1 Latin America Hospital Acquired Pneumonia Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Hospital Acquired Pneumonia Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Hospital Acquired Pneumonia Drugs Forecasted Market Size by Country
8.2.1 Latin America Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Hospital Acquired Pneumonia Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Hospital Acquired Pneumonia Drugs by Country
9.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Basilea Pharmaceutica
10.1.1 Basilea Pharmaceutica Company Information
10.1.2 Basilea Pharmaceutica Introduction and Business Overview
10.1.3 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Products Offered
10.1.5 Basilea Pharmaceutica Recent Development
10.2 Meiji Holdings
10.2.1 Meiji Holdings Company Information
10.2.2 Meiji Holdings Introduction and Business Overview
10.2.3 Meiji Holdings Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Meiji Holdings Hospital Acquired Pneumonia Drugs Products Offered
10.2.5 Meiji Holdings Recent Development
10.3 Cubist Pharmaceutical
10.3.1 Cubist Pharmaceutical Company Information
10.3.2 Cubist Pharmaceutical Introduction and Business Overview
10.3.3 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Products Offered
10.3.5 Cubist Pharmaceutical Recent Development
10.4 Aridis Pharmaceutical
10.4.1 Aridis Pharmaceutical Company Information
10.4.2 Aridis Pharmaceutical Introduction and Business Overview
10.4.3 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Products Offered
10.4.5 Aridis Pharmaceutical Recent Development
10.5 Valneva
10.5.1 Valneva Company Information
10.5.2 Valneva Introduction and Business Overview
10.5.3 Valneva Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Valneva Hospital Acquired Pneumonia Drugs Products Offered
10.5.5 Valneva Recent Development
10.6 Bayer
10.6.1 Bayer Company Information
10.6.2 Bayer Introduction and Business Overview
10.6.3 Bayer Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Bayer Hospital Acquired Pneumonia Drugs Products Offered
10.6.5 Bayer Recent Development
10.7 GlaxoSmithKline
10.7.1 GlaxoSmithKline Company Information
10.7.2 GlaxoSmithKline Introduction and Business Overview
10.7.3 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Products Offered
10.7.5 GlaxoSmithKline Recent Development
10.8 Merck
10.8.1 Merck Company Information
10.8.2 Merck Introduction and Business Overview
10.8.3 Merck Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Merck Hospital Acquired Pneumonia Drugs Products Offered
10.8.5 Merck Recent Development
10.9 Achaogen
10.9.1 Achaogen Company Information
10.9.2 Achaogen Introduction and Business Overview
10.9.3 Achaogen Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Achaogen Hospital Acquired Pneumonia Drugs Products Offered
10.9.5 Achaogen Recent Development
10.10 AstraZeneca
10.10.1 AstraZeneca Company Information
10.10.2 AstraZeneca Introduction and Business Overview
10.10.3 AstraZeneca Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 AstraZeneca Hospital Acquired Pneumonia Drugs Products Offered
10.10.5 AstraZeneca Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Hospital Acquired Pneumonia Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Hospital Acquired Pneumonia Drugs Industrial Chain Analysis
11.4 Hospital Acquired Pneumonia Drugs Market Dynamics
11.4.1 Hospital Acquired Pneumonia Drugs Industry Trends
11.4.2 Hospital Acquired Pneumonia Drugs Market Drivers
11.4.3 Hospital Acquired Pneumonia Drugs Market Challenges
11.4.4 Hospital Acquired Pneumonia Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Hospital Acquired Pneumonia Drugs Distributors
12.3 Hospital Acquired Pneumonia Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock